Highlights PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Market Closed - Canadian Securities Exchange Other stock markets 02:50:18 2024-07-12 pm EDT			5-day change	1st Jan Change
0.225 ^CAD	+2.27%		+4.65%	-28.57%

May. 15	PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine	MT
May. 10	PharmaTher Assigned FDA Approval Goal Date for its New Drug Application for Ketamine	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine	May. 15	MT
PharmaTher Assigned FDA Approval Goal Date for its New Drug Application for Ketamine	May. 10	MT
PharmaTher Brief: Announcing Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine	May. 10	MT
PharmaTher Holdings Ltd. Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine	May. 10	CI
PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia	May. 01	MT
PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 22	CI
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	Apr. 16	MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	Apr. 16	CI
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine	Feb. 12	MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	Feb. 12	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	Jan. 26	CI
PharmaTher Provided Update for Expected FDA Approval of Ketamine	Jan. 10	MT
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine	Jan. 10	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-30	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2023	23-09-28	CI
PharmaTher Announced FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for Ketarx	23-09-27	MT
PharmaTher Brief: Notes FDA assigns GDUFA goal date of April 29, 2024	23-09-27	MT
PharmaTher Brief: Announcing FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)	23-09-27	MT
PharmaTher Holdings Ltd. Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM)	23-09-27	CI
PharmaTher Submits Priority Original Abbreviated New Drug Application for Ketarx (Ketamine) to FDA	23-09-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Highlights

Filters